Sandoz’s Biosimilar Launch Eyed For May 11 Or Earlier, Absent Court Injunction

Novartis division delays Zarxio rollout to let courts consider Amgen’s request for preliminary injunction after earlier ruling in Sandoz’s favor; separately, FDA denies Amgen’s bid to require biosimilar applicants to certify they’ll join the patent dance.